VEGFA and soft tissue sarcoma: Pazopanib, a multi-kinase vascular endothelial growth factor (VEGF) based tyrosine kinase inhibitor (TKI) was the first targeted therapy approved in 2012 in the United States for the treatment of patients with advanced and metastatic soft tissue sarcomas who have progressed on standard chemotherapy (anthracycline as well as gemcitabine or ifosfamide).